Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study - Centre Eugène Marquis Accéder directement au contenu
Article Dans Une Revue JNCI Cancer Spectrum Année : 2023

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study

Sylvain Manfredi
  • Fonction : Auteur
  • PersonId : 1014888
Romain Coriat
Eric Terrebonne
  • Fonction : Auteur
  • PersonId : 1025572
Thomas Walter
Christophe Locher
  • Fonction : Auteur
  • PersonId : 1028170
Simon Pernot
  • Fonction : Auteur
  • PersonId : 1125182
Vincent Hautefeuille
  • Fonction : Auteur
Pauline Afchain

Résumé

BACKGROUND: Small bowel adenocarcinoma is a rare cancer, and the role of adjuvant chemotherapy for localized disease is still debated. METHODS: This retrospective multicenter study included all consecutive patients who underwent curative surgical resection for localized small bowel adenocarcinoma between 1996 and 2019 from 3 French cohort studies. Prognostic and predictive factors of adjuvant chemotherapy efficacy were analyzed for disease-free survival and overall survival. The inverse probability of treatment weighting method was applied in the Cox regression model using the propensity score derived from multivariable logistic regression. RESULTS: A total of 354 patients were included: median age, 63.5 years; duodenum location, 53.5%; and tumor stage I, II, and III in 31 (8.7%), 144 (40.7%), and 179 (50.6%) patients, respectively. The adjuvant chemotherapy was administered in 0 (0%), 66 (48.5%), and 143 (80.3%) patients with stage I, II, and III, respectively (P < .0001). In the subgroup analysis by inverse probability of treatment weighting method, a statistically significant disease-free survival and overall survival benefit in favor of adjuvant chemotherapy was observed in high-risk stage II (T4 and/or <8 lymph nodes examined) and III (T4 and/or N2) but not for low-risk stage II (T3 and ≥8 lymph nodes examined) and III (T1-3/N1) tumors (Pinteraction < .05). Furthermore, tumor location in jejunum and ileum was also a statistically significant predictive factor of response to adjuvant chemotherapy in stage II and III tumors (Pinteraction < .05). CONCLUSION: In localized small bowel adenocarcinoma, adjuvant chemotherapy seems to provide a statistically significant survival benefit for high-risk stage II and III tumors and for jejunum and ileum tumor locations.

Domaines

Cancer
Fichier principal
Vignette du fichier
pkad064.pdf (743.84 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04282951 , version 1 (13-11-2023)

Licence

Identifiants

Citer

Aziz Zaanan, Julie Henriques, Anthony Turpin, Sylvain Manfredi, Romain Coriat, et al.. Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study. JNCI Cancer Spectrum, 2023, 7 (5), pkad064. ⟨10.1093/jncics/pkad064⟩. ⟨hal-04282951⟩
105 Consultations
15 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More